Century Therapeutics, Inc.

NASDAQ:IPSC

Biotechnology

Healthcare
$1.38 +0.48%

+$0.01 today

Market cap
$250.60M
Beta
1.57
P/E (TTM)
-1.8
EPS (TTM)
-$1.25
52W Low $0.44High $3.04

Volume 1.14M

Average 1.12M

IPSC Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Century Therapeutics, Inc.NASDAQ: IPSC

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 86.56M shares rose 0.5% year over year, behind the +4.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +14.4% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.5% toward the trailing-twelve-month pace of +4.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
86.56M+0.0% QoQ
Last fiscal yearDec 2025
86.56M+10.1% YoY
LTMMar 2026
86.45M+4.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.5%——
1 year+10.1%——
3-year CAGR+14.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
86.56M USD
Year-over-year change
+10.1%
4-year CAGR
+12.0%

Weighted Avg Shares (Diluted) vs competitors

How IPSC compares with its peers on the latest reported figures

  • IPSC's LTM Mar 2026 weighted avg shares (diluted) of 86.45M shares is the highest of the 8 companies compared; the peer median is 28.35M shares.
  • Its year-over-year change of +4.3% is the 6th highest of 8, against a peer median of +14.4%.
  • Over three fiscal years its annual growth of +14.4% compares with a peer median of +26.1%.
IPSC Competitors Peer median
Weighted Avg Shares (Diluted) for IPSC and competitors
Company Period LTM YoY 3-year CAGR
IPSCCentury Therapeutics, Inc.LTM Mar 202686.45M +4.3%+14.4%
EQEquillium, Inc.LTM Mar 202664.9M +81.6%+39.7%
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 202632.45M +9.5%+2.2%
OSTXOS Therapies IncorporatedLTM Mar 202631.25M -31.1%+8.2%
OTLKOutlook Therapeutics, Inc.LTM Mar 202628.35M +14.4%+33.9%
KPTIKaryopharm Therapeutics Inc.LTM Mar 202615M +69.0%+26.1%
COEPCoeptis Therapeutics, Inc.LTM Mar 20264.68M -77.3%-33.3%
CUECue Biopharma, Inc.LTM Mar 20263.76M +80.5%+38.5%
Peer median (excluding IPSC) 28.35M+14.4%+26.1%

Competitors are the stored peer set for IPSC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue05.2M2.24M6.59M109.16M
Cost of Revenue4.58M00013.1M
Gross Profit(4.58M)5.2M2.24M6.59M96.06M
Gross Margin—100.0%100.0%100.0%88.0%
Research & Development75.65M97.17M92.71M107.24M95.67M
Selling, General & Admin14.65M31.86M34.71M33.16M24M
Operating Expenses90.3M139.03M148.78M144.73M111.1M
Depreciation & Amortization4.58M8.44M13.04M13.3M13.1M
EBITDA(89.92M)(121.2M)(121.21M)(111.47M)3.45M
EBITDA Margin—-2331.2%-5423.2%-1691.8%3.2%
Operating Income(94.88M)(133.83M)(146.55M)(138.14M)(15.04M)
Operating Margin—-2574.2%-6556.9%-2096.5%-13.8%
Interest Income898K2.99M12.68M13.01M7.35M
Interest Expense1.28M0540K00
Other Income / Expenses(898K)2.99M11.75M13.36M5.39M
Income Before Tax(95.78M)(130.84M)(134.79M)(124.78M)(9.65M)
Pre-Tax Margin—-2516.7%-6031.0%-1893.7%-8.8%
Income Tax Expense43K91K1.88M1.79M(68K)
Net Income(95.82M)(130.93M)(136.67M)(126.57M)(9.58M)
Net Margin—-2518.4%-6115.1%-1920.9%-8.8%
EPS (Basic)(1.74)(2.27)(2.30)(1.61)(0.11)
EPS (Diluted)(1.74)(2.27)(2.30)(1.61)(0.11)
Weighted Avg Shares55.01M57.76M59.31M78.65M86.56M
Weighted Avg Shares (Diluted)55.01M57.76M59.31M78.65M86.56M

Century Therapeutics, Inc.

NASDAQ:IPSC

Intrinsic Alpha fair value

Locked

Current Price

$1.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.